These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 32267687)

  • 1. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
    Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
    J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entinostat-Bortezomib Hybrids against Multiple Myeloma.
    Ferro A; Graikioti D; Gezer E; Athanassopoulos CM; Cuendet M
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
    J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
    Kim B; Kim SH; Jeong SJ; Sohn EJ; Jung JH; Lee MH; Kim SH
    J Agric Food Chem; 2012 Oct; 60(39):9882-9. PubMed ID: 22967175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P; Galán-Malo P; Marzo I; Naval J
    Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L; Ma YP; Jia G
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
    Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
    Zang Y; Kirk CJ; Johnson DE
    Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
    Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
    Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
    Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
    Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of second-generation proteasome inhibitors.
    Kirk CJ
    Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
    Ju D; Xie Y
    Mol Med Rep; 2014 Nov; 10(5):2609-12. PubMed ID: 25174315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
    Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.